SCHEMBL5608014

SCHEMBL5608014

Cc1nc(NC(=O)O)sc1C(=O)NCc1ccc(F)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCD O00767 3/20 0.58
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
GAA P10253 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
CHRM4 P08173 4/20 0.54
LCK P06239 1/20 0.50
CXCR4 P61073 1/20 0.48
MAOB P27338 1/20 0.48
PPARA Q07869 1/20 0.47
PKM P14618 1/20 0.47
GSK3A P49840 1/20 0.47
GSK3B P49841 1/20 0.47
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GRM4 Q14833 1/20 0.46
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL775097 0.86 LCK (0.56) SCDNPC1RAB9AGAAMEN1
SCHEMBL243781 0.84 SCD (0.61) SCDGAACHRM4CXCR4MAOB
SCHEMBL3579989 0.78 SCD (0.64) SCDNPC1RAB9AGAAMEN1
SCHEMBL3589249 0.78 SCD (0.62) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL3581698 0.77 RAB9A (0.69) SCDNPC1RAB9AGAAMEN1
SCHEMBL3587287 0.77 SCD (0.65) SCDNPC1RAB9AGAAMEN1
SCHEMBL3585444 0.77 KDM4E (0.63) SCDNPC1RAB9AGAAMEN1
SCHEMBL14871550 0.77 SCD (0.61) SCDNPC1RAB9AGAAMEN1
SCHEMBL3577784 0.76 SCD (0.67) SCDNPC1RAB9AGAAMEN1
SCHEMBL4030640 0.76 SMN1; SMN2 (0.54) SCDKMT2ACHRM4CXCR4MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758564-A2 SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER Brystol-Myers Squibb Company (US) 2007-03-07 EP disclosed
WO-2005094376-A2 SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-13 WO disclosed